Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
91
ISIN
US47103J1051
Website
JANX Metrics
BasicAdvanced
$1.6B
-
-$1.37
3.24
-
Price and volume
Market cap
$1.6B
Beta
3.24
52-week high
$64.87
52-week low
$22.48
Average daily volume
723K
Financial strength
Current ratio
58.47
Quick ratio
58.264
Long term debt to equity
2.054
Total debt to equity
2.233
Profitability
EBITDA (TTM)
-111.536
Gross margin (TTM)
-750.18%
Net profit margin (TTM)
-832.71%
Operating margin (TTM)
-1,216.61%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-8.16%
Return on equity (TTM)
-9.32%
Valuation
Price to revenue (TTM)
169.238
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-33.954
Free cash flow yield (TTM)
-2.95%
Free cash flow per share (TTM)
-81.73%
Growth
Revenue change (TTM)
28.12%
Earnings per share change (TTM)
12.58%
3-year revenue growth (CAGR)
24.43%
3-year earnings per share growth (CAGR)
1.54%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
Bulls say / Bears say
Janux Therapeutics successfully closed a public offering, raising $402.5 million to advance its clinical pipeline, indicating strong financial backing for future developments. (Janux Therapeutics)
The company reported a $7.5 million milestone payment from Merck, reflecting progress in its collaborative efforts and validation of its TRACTr and TRACIr platforms. (Business Wire)
Analysts have raised the price target for Janux Therapeutics to $100.00, suggesting confidence in the company's growth potential and future performance. (American Banking and Market News)
Significant stock sales by major shareholders, totaling approximately $23.8 million, may indicate reduced confidence or profit-taking, potentially impacting investor sentiment. (Investing.com)
Despite promising early-stage results, analysts believe Janux has not yet established a strong competitive edge, which could affect its attractiveness for partnerships or acquisitions. (Nasdaq)
The company's reliance on ongoing clinical trials for its lead candidates, JANX007 and JANX008, means that any setbacks or delays could negatively impact its stock performance and investor confidence. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
JANX News
AllArticlesVideos
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
Business Wire·21 hours ago
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
Business Wire·2 months ago
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $1.6B as of July 18, 2025.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of July 18, 2025.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 3.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.